This article is more than 5 years old. Information may no longer be current.

Nicox, Bausch + Lomb restructure Vyzulta financial terms

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Nicox and Bausch + Lomb have agreed to new financial terms for Vyzulta, which includes an additional $20 million in potential milestone payments, according to a press release.

The original global licensing agreement between the companies included Nicox receiving 10% to 15% of royalties on worldwide net sales of Vyzulta (latanoprostene bunod ophthalmic solution 0.024%), with three tiers triggered by increasing, predefined annual sales levels, the release said.

Under the terms of the new agreement, Bausch + Lomb will pay Nicox an additional 1% over the original royalty on net sales more than $300 million annually, totaling 10% to 16% over four tiers.

Potential milestone payments due to Nicox will also be increased by $20 million to $165 million, which will be added to and split among three existing milestones at annual net sales levels beginning with $300 million.